Free tool
Rare disease stocks
We cover 2 companies grouped under the Rare disease theme. The median market value in the group is $61.22B. Across the group, the median move over the past trading day is −0.46%. Price change over the past year runs from +17.6% to +38.2% across the middle 80 percent of the group, with a median of +27.9%.
Other lists in this group
SaaSAI applicationsCybersecuritySemiconductor designSemiconductor equipmentFintech softwarePayment processingEcommerce marketplacesStreaming mediaGaming softwareOncologyRare diseaseMedical devicesCell therapyDiagnosticsRegional banksAsset managementGold miningCryptocurrency and digital assetsSpecialty chemicalsAll stocks
Table
2 of 268 companies match these filters.Clear filters
| Ticker | Company | Market cap (USD) | Size | 1Y return |
|---|---|---|---|---|
| 0QZU.L | Vertex Pharmaceuticals Incorporated | $112.52B | Large cap | +40.77% |
| 0HNC.L | BioMarin Pharmaceutical Inc. | $9.93B | Mid cap | +15.03% |
Covers ~22,000 companies across the US, Europe and Asia-Pacific (ex mainland China, Hong Kong and India), refreshed nightly. Every listed stock opens as a full analysis for $9.90.